Kyprolis (Carfilzomib) Patent Expiration, LOE Window & CMS Spending

Kyprolis (Carfilzomib) by Amgen: FDA Orange Book core substance LOE 2027-01-20 (last listed 2041-10-29), 0 AB generics, $52.5M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN202714 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-01-20
Last Listed Patent or Exclusivity Date2041-10-29
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$52.5M
2024 Medicare Part D Spend$17.7M
2024 Medicaid Spend$34.8M
Reported Wholesale Price Change (CA SB 17)16 WAC filings (max 27.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.